Pneumonia with Cystic Fibrosis Medications
Drugs associated with Pneumonia with Cystic Fibrosis
The following drugs and medications are in some way related to, or used in the treatment of Pneumonia with Cystic Fibrosis. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
Pneumonia with Cystic Fibrosis Medications in the Pipeline
- October 26, 2009 - Gilead's Aztreonam for Inhalation Solution to be Reviewed by FDA Anti-Infective Drugs Advisory Committee on December 10, 2009
- February 19, 2009 - Gilead Receives Response From U.S. FDA on Company's Request for Formal Dispute Resolution for Aztreonam for Inhalation Solution
- September 17, 2008 - Gilead Receives Complete Response Letter from U.S. Food and Drug Administration for Aztreonam Lysine for Inhalation, an Investigational Treatment for Cystic Fibrosis
- November 26, 2007 - PARI's eFlow Included in Gilead's NDA Submission for Aztreonam Lysine for Inhalation
- November 16, 2007 - Gilead Submits New Drug Application to U.S. FDA for Aztreonam Lysine for Inhalation for Cystic Fibrosis
Latest Pneumonia with Cystic Fibrosis Blog Post
PARI Pharma Completes Successful Clinical Trials for Tobramycin 100 & Investigational eFlow for CF
MONTEREY, Calif., November 10, 2008 /PRNewswire/ -- PARI Pharma GmbH has successfully completed Phase I and Phase II clinical trials comparing its proprietary PARI Tobramycin 100 (150mg/1.5mL) formulation delivered via a customized Investigational eFlow...
View all Pneumonia with Cystic Fibrosis blog posts.
